Trial NCT03674827

View at ClinicalTrials.gov 
Org. Study IDs: C3621001
Secondary IDs: VBIR-2

Last trial update was posted on 2022-05-05

MeSH Interventions

Immunomodulating Agents

MeSH Conditions

Breast Neoplasms Carcinoma, Non-Small-Cell Lung Lung Neoplasms Triple Negative Breast Neoplasms

Other Conditions

Non-Small Cell Lung Cancer Triple-negative Breast Cancer

Stopping Reasons

The study was terminated due to the review of the asset (VBIR-2) within the Sponsor's oncology portfolio; the study was not terminated because of safety concerns.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID